Achieving Low Disease Activity in Lupus Nephritis: A Step Forward in Management
Achieving a low disease activity state in lupus nephritis significantly reduces relapse risk and helps preserve kidney function, offering hope for better long-term management of the condition.
Recent research highlights that achieving a low disease activity state (LLDAS) in patients with lupus nephritis is possible and is associated with improved outcomes. A study published online in Arthritis Care & Research on July 20, 2025, demonstrates that both complete renal response (CRR)/partial renal response (PRR) and LLDAS are linked to higher relapse-free survival rates. The study involved 245 adult lupus nephritis patients, with findings revealing that 40% achieved CRR, 10% achieved PRR, and 49% attained LLDAS after 12 months.
The research, led by Chak Kwan Cheung from The University of Hong Kong, shows that attaining these treatment targets independently reduces the risk of disease relapse and helps preserve kidney function long-term. Specifically, achieving CRR/PRR and LLDAS was associated with hazard ratios of 0.31 and 0.38, respectively, indicating a significant decrease in relapse risk.
Importantly, the study emphasizes that LLDAS can be an attainable and effective treatment goal in lupus nephritis management. The authors suggest that aiming for LLDAS, either alone or alongside CRR/PRR, leads to better patient outcomes, including a lower chance of disease relapse and better renal function preservation.
This evidence encourages clinicians to incorporate LLDAS into treatment protocols, helping improve long-term quality of life for patients with lupus nephritis. For further details, see the full study in Arthritis Care & Research (DOI: 10.1002/acr.25611).
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Psoriasis and Its Link to Increased Sleep Disorder Risks
Emerging research reveals a strong link between psoriasis and increased risk of sleep disorders, underscoring the importance of integrated care for affected patients.
Innovative Immunology-Based Radiation Therapy Techniques Highlighted at International Conference
Researchers at the University of Kentucky highlight innovative immunology-driven radiation therapy techniques that enhance cancer treatment while preserving immune function, showcased at a major international conference.
President Trump Advocates Against Tylenol Use During Pregnancy Despite Medical Guidance
President Donald Trump advises pregnant women to avoid Tylenol, contradicting medical guidelines that endorse its safe use for fever and pain management during pregnancy. Experts emphasize the importance of consulting healthcare providers for safe treatment options.
FDA Approves Subcutaneous Tremfya for Induction Treatment of Ulcerative Colitis
The FDA has approved a new subcutaneous Tremfya induction treatment for adults with moderate to severe ulcerative colitis, offering a convenient self-injection option with proven efficacy and safety.